CARLSBAD, Calif., Sept. 11,
2024 /PRNewswire/ -- Tyra Biosciences, Inc.
(Nasdaq: TYRA), a clinical-stage biotechnology company focused on
developing next-generation precision medicines that target large
opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
announced today its participation at the 2024 Cantor Global
Healthcare Conference.
Todd Harris, CEO of TYRA, will
participate in a fireside chat on Tuesday,
September 17, 2024, at 9:45 am
ET. TYRA management will also participate in
one-on-one meetings with investors during the conference.
A live and archived webcast of the fireside chat will be
available via the For Investors page on the Investor
section of the TYRA website.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage
biotechnology company focused on developing next-generation
precision medicines that target large opportunities in FGFR
biology. The Company's in-house precision medicine platform, SNÅP,
enables rapid and precise drug design through iterative molecular
SNÅPshots that help predict genetic alterations most likely to
cause acquired resistance to existing therapies. TYRA's initial
focus is on applying its accelerated small molecule drug discovery
engine to develop therapies in targeted oncology and genetically
defined conditions. TYRA is based in Carlsbad, CA.
For more information about our science, pipeline and people,
please visit www.tyra.bio and engage with us on
LinkedIn.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-the-2024-cantor-global-healthcare-conference-302245618.html
SOURCE Tyra Biosciences
